- Demonstrates Neurophet AQUA AD for AD treatments such as
Leqembi and Kisunla
- Introduces updated version of Neurophet SCALE PET with
centiloid scale feature
SEOUL,
South Korea, July 25,
2024 /PRNewswire/ -- Neurophet, an artificial
intelligence (AI) solution company for brain disease, announced its
participation in the Alzheimer's Association International
Conference (AAIC 2024) which will be held in Philadelphia, U.S.A.
At the upcoming AAIC, Neurophet will launch 'Neurophet AQUA AD',
the software for Alzheimer's disease (AD) treatment
prescription and monitoring treatment effects and side effects.
Neurophet AQUA AD is an integrated solution of cutting-edge brain
image analysis technology related to AD treatments. This solution
is currently preparing for medical device certifications in Korea,
the U.S., and Japan.
Neurophet will offer demonstrations of Neurophet AQUA AD and
showcase brain PET image analysis software 'Neurophet SCALE
PET' with the major features updated at the company's booth.
The AD treatment market is set to grow in earnest with this
month's FDA approval of Eli Lilly's newest AD treatment Kisunla
(donanemab) following Leqembi (lecanemab) which was developed by
global pharmaceutical companies Eisai in Japan and Biogen in the U.S.
Anti-amyloid treatments like Kisunla and Leqembi bear a warning
on the risk of amyloid-related imaging abnormalities (ARIA), which
are known as side effects showing edema and microhemorrhages. In
fact, ARIA has been reported in 20-30% of patients participating in
clinical trials of both treatments. Patients undergoing
anti-amyloid treatments are required to scan MRI at least 5~6 times
a year for monitoring ARIA.
Neurophet AQUA AD is a software providing all the brain imaging
biomarker analysis features required during the administration of
anti-amyloid treatments, by quantitatively analyzing MRI and PET
images. It is possible to determine the patients' eligibility to
prescribe the treatment before administration, monitor ARIA during
administration, and analyze the effects of the treatment due to the
reduction of amyloid beta deposited in the brain.
In addition, Neurophet will introduce a significantly updated
version of Neurophet SCALE PET with centiloid scale feature. The
centiloid scale quantitatively determines the positivity and
negativity of amyloid PET images and standardizes amyloid plaque
deposition from 1 to 100 in amyloid PET even when different tracers
are used.
"We are excited to unveil our groundbreaking total solution for
AD treatments at AAIC which is the global conference gathering
scholars all over the world," said CEO Jake Junkil Been of
Neurophet. "We expect the use of Neurophet AQUA AD, a specialized
technology for brain image analysis related to AD treatments, to be
extremely high."
The AAIC is the world's largest conference for the advancement
of dementia research, bringing dementia researchers, clinicians,
and professionals together to share research and clinical practice
on diagnosis, risk reduction, and treatment improvement of AD and
other types of dementia. AAIC takes place in Philadelphia, U.S.A. this year, which starts on July 28th (local time) and runs until
August 1st.
About Neurophet
Neurophet has specialized in developing solutions for diagnosis
support, treatment guides, and treatment devices targeting brain
diseases based on cutting-edge artificial intelligence (AI)
technology. The company was founded in 2016 by Jake Junkil Been,
CEO, and Donghyeon Kim, CTO, who developed the next-generation
neuro-navigation system.
Major products include brain MRI analysis software "Neurophet
AQUA", brain PET image analysis (PET tracer deposition) software
"Neurophet SCALE PET", brain imaging treatment planning software
for electric and magnetic brain stimulation "Neurophet tES/TMS
LAB".
Neurophet has set its top priority to helping patients suffering
from brain diseases. Based on expertise in neuroscience, Neurophet
will continue to challenge and grow to explore the human brain's
health and pioneer solutions for brain diseases with AI
technology.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/neurophet-to-launch-total-solution-for-ad-treatments-neurophet-aqua-ad-at-aaic-2024-302204882.html
SOURCE Neurophet